For a patient treated with abiraterone for first line metastatic prostate cancer, would you still use a combination of abiraterone/olaparib at a subsequent progression?

No, there is no evidence for this, and in the absence of benefit, I would use single agent olaparib in HRD+ patients only, particularly BRCA2 patients. Ongoing trials like the CASPAR trial will address this question. In addition, there are ongoing trials testing PARP/AR combinations in men with mHSP...

This was not the PROpel population – if abiraterone was continued from the metastatic hormone sensitive setting to the metastatic castration resistance setting, I don’t think adding Olaparib directly to abiraterone will salvage the abiraterone resistance.